Kestra Medical Technologies (NASDAQ:KMTS) Director Mary Kay Ladone Sells 3,908 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Mary Kay Ladone sold 3,908 shares of Kestra Medical Technologies stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.20, for a total value of $98,481.60. Following the transaction, the director owned 37,507 shares in the company, valued at approximately $945,176.40. This represents a 9.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 2.1%

Shares of Kestra Medical Technologies stock opened at $23.57 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $30.00. The firm has a market cap of $1.38 billion, a PE ratio of -9.74 and a beta of 0.62. The business’s 50 day simple moving average is $25.42 and its 200 day simple moving average is $22.71.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KMTS has been the topic of a number of research reports. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.14.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to the executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development efforts. He will oversee innovation for the Cardiac Recovery System platform, including strategic partnerships and artificial-intelligence initiatives. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, indicating no measurable short-selling pressure based on the filing data. However, the figure provides little incremental insight because it was also reported as zero in the prior period.
• Negative Sentiment: Four directors disclosed sales totaling about 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by roughly 9% to 48%. All four sales were explicitly made to cover tax-withholding obligations tied to vested equity awards, which makes them less bearish than discretionary open-market selling, but the cluster of transactions may still pressure sentiment. SEC insider transaction filing
• Negative Sentiment: Kestra’s latest reported quarter included an adjusted loss of $0.67 per share, worse than the $0.59 analyst consensus, alongside $28.64 million in revenue. The company remains unprofitable, increasing investor sensitivity to execution, product adoption and commercialization risks.

Institutional Trading of Kestra Medical Technologies

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its position in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies during the 4th quarter worth $72,000. BNP Paribas Financial Markets boosted its stake in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in Kestra Medical Technologies by 34.6% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after acquiring an additional 1,392 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.